BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 8546482)

  • 1. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications.
    Wasik MA; Vonderheid EC; Bigler RD; Marti R; Lessin SR; Polansky M; Kadin ME
    Arch Dermatol; 1996 Jan; 132(1):42-7. PubMed ID: 8546482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
    Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
    Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable?
    Rao V; Ryggen K; Aarhaug M; Dai HY; Jørstad S; Moen T
    J Eur Acad Dermatol Venereol; 2006 Oct; 20(9):1100-7. PubMed ID: 16987266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
    Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment.
    Goldman BD; Oh SK; Davis BE; Kadin ME; Poiesz BJ; Koh HK
    Arch Dermatol; 1993 Sep; 129(9):1166-70. PubMed ID: 8363402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological immunomarkers in cutaneous T cell lymphoma.
    Hassel JC; Meier R; Joller-Jemelka H; Burg G; Dummer R
    Dermatology; 2004; 209(4):296-300. PubMed ID: 15539892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
    J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
    Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
    Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble interleukin-2 receptor in stage I-III melanoma.
    Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
    Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.
    Oka M; Hazama S; Takahashi M; Yamamoto K; Abe T; Yoshino S; Hayashi H; Tangoku A
    Hepatogastroenterology; 1999; 46(28):2254-9. PubMed ID: 10521976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis.
    Miyagaki T; Sugaya M
    J Dermatol Sci; 2011 Oct; 64(1):1-6. PubMed ID: 21872448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
    Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
    Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of serum biological markers in patients with hepatocellular carcinoma.
    Parasole R; Izzo F; Perrone F; Pignata S; Galati MG; Leonardi E; Castiglione F; Orlando R; Castello G; Esposito G; Gallo C; Daniele B
    Clin Cancer Res; 2001 Nov; 7(11):3504-9. PubMed ID: 11705869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
    Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
    Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
    Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
    Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
    Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
    Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.